Open AccessOctreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients
Author(s) -
SW van Thiel,
JA Romijn,
NR Biermasz,
BE Ballieux,
M. Frölich,
Johannes W. A. Smit,
EP Corssmit,
Ferdinand Roelfsema,
Alberto M. Pereira
Publication year - 2004
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje.0.1500489
Subject(s) - acromegaly , octreotide , somatostatin , lanreotide , medicine , endocrinology , somatostatin receptor , hormone , growth hormone , chemistry
Recently a new depot preparation of the long-acting somatostatin analogue, lanreotide Autogel was introduced for the treatment of acromegaly. Like octreotide long-acting repeatable (LAR), it has high binding affinity for the somatostatin receptor subtype SSTR 2 and less binding affinity for SSTR 5. We hypothesized that the ability to suppress growth hormone (GH) secretion in patients with acromegaly would be similar for these depot preparations.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom